Novo Nordisk sues Eli Lilly over alleged misleading GLP-1 ads

• Novo specifically objects to ads comparing Zepbound to the 2.4mg dose of Wegovy (showing 50 lbs vs 33 lbs weight loss), which exclude data on Novo's new 7.2mg high-dose Wegovy approved in March that shows comparable 47 lb average weight loss
• The Zepbound TV commercial has received over 700 million impressions since late April, demonstrating significant competitive impact on Novo's market position
• Novo is bringing federal and state unfair competition claims under the Lanham Act, arguing no head-to-head trials exist comparing the highest doses of both drugs, so Lilly lacks basis for superiority claims

Summary

Key Development: Novo Nordisk filed a lawsuit against Eli Lilly in U.S. District Court for the District of New Jersey, alleging misleading advertising in the highly competitive GLP-1 drug market for obesity and diabetes treatments.

Core Allegations: Novo claims Lilly's nationwide TV and social media campaigns use "outdated" clinical trial data to unfairly compare drugs. Specifically, Lilly's ads compare the highest doses of its drugs (Zepbound and Mounjaro) against lower doses of Novo's products (Wegovy and Ozempic), omitting newer data on Novo's higher-dose formulations.

Specific Example: Lilly's TV commercial claims Zepbound patients lose 50 pounds on average versus 33 pounds on the 2.4mg dose of Wegovy. However, Novo's recently approved 7.2mg Wegovy dose (launched March) shows average weight loss of 47 pounds—"clinically consistent" with Zepbound results. This higher dose is only mentioned in "small footnote" that Novo calls "virtually illegible."

Legal Actions: Novo is pursuing federal and state unfair competition and false advertising claims under the Lanham Act. The company seeks:

• Permanent injunction against the ads
• Corrective advertising from Lilly
• Financial damages (amount unspecified)
• Preliminary injunction in coming days for immediate blocking

Market Context: The lawsuit reflects intensifying competition between pharmaceutical giants in the blockbuster GLP-1 market. Lilly's medications have recently gained preference among providers and patients due to high efficacy. Novo's high-dose Wegovy represents a direct competitive response. One Lilly commercial has already received over 700 million impressions since late April.

Novo filed suit after Lilly refused an April cease-and-desist request. Lilly has not yet commented.